![]() Half received once-a-month infusions of donanemab and half dummy infusions for 18 months. Lilly’s study enrolled people ages 60 to 85 who were in early stages of Alzheimer’s. Eric Widera of the University of California, San Francisco, wrote in a JAMA editorial accompanying Lilly’s new data. ![]() “The modest benefits would likely not be questioned by patients, clinicians or payers if amyloid antibodies were low risk, inexpensive and simple to administer. Lilly announced in May that donanemab appeared to work, but on Monday the full results of a study of 1,700 patients was published by the Journal of the American Medical Association and presented at the Alzheimer’s conference. ![]() “Diabetes doesn’t have a cure either - it doesn’t mean you can’t have very meaningful treatments for patients.” John Sims told reporters Monday at the Alzheimer’s Association International Conference in Amsterdam. “Finally there’s some hope, right, that we can talk about,” Lilly’s Dr. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease - after the recently approved Leqembi from Japanese drugmaker Eisai. is seeking Food and Drug Administration approval of donanemab. WASHINGTON (AP) - Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening - by about four to seven months, researchers reported Monday.Įli Lilly and Co.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |